The IGF1R antagonist, AMG 479, has shown promising results in the treatment of ESFTs in a phase I clinical trial, indicating that Ewing Sarcomas may be particularly sensitive to intervention of the IGF1R signaling pathway [110, 111]. This evidence concerns the gene IGF1R and Ewing sarcoma.